prazosin has been researched along with Idiopathic Parkinson Disease in 8 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mild dizziness/lightheadedness was more common in the TZ group, and three participants taking TZ dropped out because of dizziness and/or orthostatic hypotension." | 3.11 | A pilot to assess target engagement of terazosin in Parkinson's disease. ( Brinker, AN; Ernst, SE; Liu, L; Magnotta, VA; Narayanan, NS; Rauckhorst, AJ; Schultz, JL; Simmering, JE; Taylor, EB; Tayyari, F; Uc, EY; Welsh, MJ; Xu, J, 2022) |
| " Additional dose-response analyses were carried out." | 1.62 | Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease. ( Liu, L; Narayanan, NS; Pottegård, A; Simmering, JE; Welsh, MJ, 2021) |
| "We found slower disease progression, decreased PD-related complications, and a reduced frequency of PD diagnoses in individuals taking TZ and related drugs." | 1.51 | Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. ( Cai, R; Chen, Z; Consiglio, A; Fernandez-Carasa, I; Gao, L; Han, Y; Ji, X; Li, Y; Liu, L; Narayanan, NS; Polgreen, PM; Raya, A; Schultz, JL; Simmering, JE; Su, W; Welsh, MJ; Yuan, Y; Zhang, Y; Zhao, C, 2019) |
| "Further, when the HAL (1 mg/kg) catalepsy score was maximal (at 120 min), the rats were subjected to cold stress (3 degrees C for 10 min) or treated with NA, AD (2 micrograms/kg, i." | 1.29 | Glucocorticoids attenuate haloperidol-induced catalepsy through adrenal catecholamines. ( Chopde, CT; Hote, MS; Mandhane, SN; Muthal, AV, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Schultz, JL | 2 |
| Brinker, AN | 1 |
| Xu, J | 1 |
| Ernst, SE | 1 |
| Tayyari, F | 1 |
| Rauckhorst, AJ | 1 |
| Liu, L | 3 |
| Uc, EY | 1 |
| Taylor, EB | 1 |
| Simmering, JE | 3 |
| Magnotta, VA | 1 |
| Welsh, MJ | 3 |
| Narayanan, NS | 3 |
| Sardoiwala, MN | 1 |
| Mohanbhai, SJ | 1 |
| Karmakar, S | 1 |
| Choudhury, SR | 1 |
| Cai, R | 1 |
| Zhang, Y | 1 |
| Li, Y | 1 |
| Fernandez-Carasa, I | 1 |
| Consiglio, A | 1 |
| Raya, A | 1 |
| Polgreen, PM | 1 |
| Yuan, Y | 1 |
| Chen, Z | 1 |
| Su, W | 1 |
| Han, Y | 1 |
| Zhao, C | 1 |
| Gao, L | 1 |
| Ji, X | 1 |
| Foltynie, T | 1 |
| Pottegård, A | 1 |
| Cash, R | 2 |
| Ruberg, M | 1 |
| Raisman, R | 1 |
| Agid, Y | 2 |
| Chopde, CT | 1 |
| Hote, MS | 1 |
| Mandhane, SN | 1 |
| Muthal, AV | 1 |
| Lasbennes, F | 1 |
| Sercombe, R | 1 |
| Seylaz, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| a Randomized, Double Blind, Placebo Controlled Clinical Trial Exploring the Target Engagement and Tolerability of Terazosin Hydrochloride in Patients With Dementia With Lewy Bodies[NCT04760860] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 2024-10-31 | Not yet recruiting | ||
| The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-09-23 | Recruiting | ||
| Assessing Target Engagement of Terazosin in Healthy Adults[NCT04551040] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-03-26 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for prazosin and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Glycolysis as a therapeutic target for Parkinson's disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Drug Delivery Systems; Glycolysis; Humans; Parkins | 2019 |
1 trial available for prazosin and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
A pilot to assess target engagement of terazosin in Parkinson's disease.
Topics: Adenosine Triphosphate; Dizziness; Humans; Parkinson Disease; Pilot Projects; Prazosin | 2022 |
6 other studies available for prazosin and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Hytrin loaded polydopamine-serotonin nanohybrid induces IDH2 mediated neuroprotective effect to alleviate Parkinson's disease.
Topics: alpha-Synuclein; Dopamine; Humans; Indoles; Neurodegenerative Diseases; Neuroprotective Agents; Park | 2022 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, | 2021 |
Adrenergic receptors in Parkinson's disease.
Topics: Clonidine; Dihydroalprenolol; Frontal Lobe; Humans; Locus Coeruleus; Neural Pathways; Norepinephrine | 1984 |
Glucocorticoids attenuate haloperidol-induced catalepsy through adrenal catecholamines.
Topics: Adrenalectomy; Animals; Catalepsy; Catecholamines; Glucocorticoids; Haloperidol; Male; Parkinson Dis | 1995 |
Adrenergic receptors on cerebral microvessels in control and parkinsonian subjects.
Topics: Aged; Alprenolol; Capillaries; Cerebrovascular Circulation; Clonidine; Dihydroalprenolol; Humans; Ki | 1985 |